Pharmaceutical

Vor Bio back from brink with autoimmune drug deal rising to $4bn

Equipped with a new CEO, Vor Bio is transitioning into an autoimmune player, leaving cell and gene therapy behind.

Jun 27, 2025 - 06:00
Vor Bio back from brink with autoimmune drug deal rising to $4bn
Equipped with a new CEO, Vor Bio is transitioning into an autoimmune player, leaving cell and gene therapy behind.
Read the original article

Tags:

Previous Article

Porton Advanced and EVA Pharma collaborate for CAR T-cell therapies

Next Article

BioCity’s SC0062 gains NMPA breakthrough therapy designation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise

Listen: ESMO highlights, Roivant’s big deal, & biotech ...

Oct 26, 2023

‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs

‘Robbing Peter to pay Paul’: Obesity experts debate ris...

May 9, 2023

Q1 2024 update: individualism & expression related M&A activity in the pharmaceutical industry

Q1 2024 update: individualism & expression related M&A ...

May 21, 2024